Biopharmaceutical companies increasingly want to convert fed-batch manufacturing processes to continuous platforms. We teamed up with GLOBAL Regulatory Writing & Consulting for this whitepaper so that you can learn:
- How to meet regulatory expectations when switching to continuous manufacturing
- The importance of appropriate risk assessments
- How to demonstrate comparability with previously manufactured material
